Pentasa Sachets 4 G 4 g Prolonged release granules

Pentasa Sachets 4 G 4 g Prolonged release granules

S3
PDF Leaflet Revision Date: 17 September 2024

API: Mesalazine | Company: Ferring

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of mild to moderate ulcerative colitis and Crohnu2019s disease.

Dosage (summary)

Adults: Up to 4 g mesalazine daily; Maintenance: 2 g once daily.

Special Populations

  • Elderly
  • Renal impairment
  • Hepatic impairment

Pregnancy & Breastfeeding

Use with caution; potential risks in pregnancy and breastfeeding.

Key Drug Interactions

  • Azathioprine
  • NSAIDs
  • Warfarin

Contraindications

  • Hypersensitivity to mesalazine
  • Severe liver and/or renal impairment

Common side effects

  • Diarrhoea
  • Nausea
  • Abdominal pain
  • Headache
  • Vomiting
  • Rash

Counselling Points

  • Do not chew granules
  • Ensure adequate fluid intake
  • Report any severe skin reactions

Serious warnings

  • Severe cutaneous adverse reactions
  • Monitor liver and renal function
Important Disclaimer

The Pentasa Sachets 4 G 4 g Prolonged release granules professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites